Bristol Myers Squibb reported a pair of Phase 3 wins tied to its fibrosis and RayzeBio programs, while noting an experimental lung drug, admilparant, posted mixed results that left analysts questioning its commercial prospects. The company’s updates set up a portfolio question: whether positive readouts can offset uncertainty created by less convincing primary outcomes in at least one program. Together, the disclosures show BMS navigating near-term evidence quality across two very different development lanes—pulmonary fibrosis drug development and radiopharmaceutical growth strategies. Investors will likely focus on endpoint strength, durability, and safety consistency as the company moves from readouts to labeling discussions.